Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927308 | 1.00 | NR1I2 (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL420311 | 1.00 | NR1I2 (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL588472 | 0.87 | APLNR (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL12069877 | 0.87 | APLNR (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL588473 | 0.87 | APLNR (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL1927306 | 0.87 | APLNR (0.48) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL15240217 | 0.80 | B3GNT2 (0.45) | MAPK1PDE2ANPC1CACNA1ISLC22A12 | |
| SCHEMBL1693739 | 0.79 | NR1I2 (0.46) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL12069878 | 0.79 | NR1I2 (0.46) | NR1I2APLNRP2RX3P2RX2MAPK1 | |
| SCHEMBL24468398 | 0.78 | APLNR (0.47) | NR1I2APLNRJAK2JAK3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| EP-2582703-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012160030-A1 | PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | NR1I2 679/4885APLNR 4087/4885P2RX3 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.